Our experts attending
Dedicated professionals committed to clinical excellence.
Meet Southern Star Research at the ASCO 2026 Annual Meeting
The ASCO Annual Meeting is where the future of cancer care takes shape—bringing together the science, strategy, and partnerships that move oncology forward.
Join Southern Star Research in Chicago or online to explore how we help biotech sponsors navigate the complexity of early-phase oncology development with clarity, speed, and confidence.
Oncology Expertise That Goes Beyond Delivery
Oncology is one of our most established and deeply embedded therapeutic areas.
We partner with biotech sponsors who need more than execution. They need a CRO that understands the science, anticipates complexity, and takes ownership—from first engagement through close-out.
Our teams bring hands-on Phase 1 oncology experience, strong investigator relationships, and a pragmatic, problem-solving mindset. Sponsors work directly with senior experts who stay close to the study—not through layers of project management.
How We Support Oncology Development
- Scientific Partnership
We engage early and think alongside your team—challenging assumptions, refining design, and anticipating risks before they impact timelines. - Early-Phase Execution
Deep experience in First-in-Human and First-in-Patient oncology studies, with a focus on dose escalation, safety, and biomarker strategy. - Nuclear Medicine & Precision Oncology
Strong capabilities in radiopharmaceutical and imaging-enabled trials, including site networks, logistics, and regulatory pathways across APAC. - Direct Access to Experts
Senior clinical and operational leaders remain actively involved throughout your study—ensuring faster decisions and clearer communication. - APAC Advantage
As a leading mid-sized CRO in APAC, we combine regional regulatory expertise and site relationships with global standards—supporting FDA, EMA, PMDA, and Health Canada pathways.
Built for Biotech
We understand the realities of small and mid-sized biotech teams—limited bandwidth, investor pressure, and the need for reliable timelines.
Our approach is deliberately different:
- Engaged, not transactional
- Flexible, not rigid
- Scientifically grounded, not process-driven
We operate in the “sweet spot”—delivering global capability with the agility and accountability of a true partner.
Let’s Connect at ASCO 2026
If you’re advancing an oncology program and need a CRO that brings both scientific depth and executional clarity, we’d welcome the conversation.
Schedule a meeting with our team at ASCO 2026 to discuss how we can support your next study.